Trial Profile
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mifepristone (Primary) ; Eribulin
- Indications Advanced breast cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Corcept Therapeutics
- 12 Jan 2018 Status changed from active, no longer recruiting to completed.
- 17 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 17 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.